Quality of Randomized Controlled Trials Reporting in the Primary Treatment of Brain Tumors

• DOI: 10.1200/jco.2005.03.1179
• Publication Date: 2006-02-28T00:37:43Z
• Authors: Rose Lai; Rong Chu; Michael Fraumeni; Lehana Thabane
• Keywords: Blinding; Critical appraisal; Quality Score; Impact factor

To assess the reporting quality of randomized controlled trials (RCTs) in primary treatment brain tumors and to identify significant predictors quality.Two investigators searched MEDLINE, EMBASE, bibliographies retrieved articles for RCTs published between January 1990 December 2004. We assessed overall key methodologic factors (allocation concealment, blinding, intention treat [ITT]). Two also rated independently using items from revised Consolidated Standards Reporting Trials statement. A generalized estimated equation was used generate regression models that identified associated with reporting.We 74 relevant randomly assigned 14,498 tumor patients. The has improved during last 15 years, but eight were reported less than 50% trials. In appraisal methodologies, allocation adherence ITT principle 30% articles. Multivariable revealed an impact factor more 1.66, publication after 1995, sample size 280 better reporting, whereas complete industrial funding, 2.64, positive outcomes higher ratings three most important qualities.Despite improvement general quality, methodologies safeguard against biases may still benefit description. Significant act as surrogates other characteristics.